Alcidion has today announced the addition of three new appointments to their UK-based team, with one internal promotion and two external recruits. Dr Paul Deffley has been announced as the UK Managing Director, with Tracy McClelland and Darren Ransley joining as global Chief Clinical Information Officer (CCIO) and Chief Revenue Officer (UK), respectively.
Dr Paul Deffley has been Alcidion’s Chief Medical Officer since 2022 and will continue in this capacity in addition to taking on the UK Managing Director responsibilities.
With 28 years of healthcare experience, Tracy McClelland joins Alcidion with a combination of deep frontline clinical expertise and senior clinical leadership in digital transformation across the UK and Australia. Tracy began her career as a Haematology and Oncology Specialist Nurse, transitioning into a global CNIO/CCIO role in digital health nine years ago.
Darren Ransley brings more than 25 years of experience in enterprise sales, growth and strategy development in healthcare. He has specialised in selling, marketing, and supporting delivery of healthcare solutions and digital health platforms. Darren will lead business development and account management for Alcidion in the UK, supporting the NHS to realise its vision of a digital future.
The appointments build on Alcidion’s established presence supporting the digital capability of the NHS. The Company’s flagship platform, Miya Precision, has been adopted by a growing number of trusts delivering data interoperability and clinical workflow transformation. Miya Precision is known as a highly user-friendly, clinician-focussed platform that supports trusts to streamline patient flow, unify patient records and deliver AI-powered clinical decision support.
The expanded team comes at a unique moment for the NHS and UK market, following the release of the ambitious NHS 10 Year plan and increasing digitisation of healthcare.
Kate Quirke, Alcidion CEO & Managing Director said: "This is truly an exciting time to be working in healthcare in the United Kingdom, and having Paul step into the MD role is great for both our customers and the future of the company. I look forward to having Tracy and Darren’s expertise on board, complementing the established capabilities of our UK and global team. Both will be crucial contributors to how we support our new and existing customers to deliver on the new NHS goals."
Dr Paul Deffley noted: "When we are building and supporting digital solutions for health, it is absolutely critical that we have the clinician’s viewpoint and that level of safety built-in. Tracy's clinical perspective will be invaluable in helping us build software that truly improves patient outcomes and supports safe, efficient operations. I am also delighted about Darren's expertise in expanding our reach across the UK and building on the strong relationships we've already established in the market."
Both Darren and Tracy commence with Alcidion on the 1st September, 2025.
About Alcidion
Alcidion (ASX:ALC) is a Global healthcare technology company that has a track record of providing leading software solutions to hospitals and healthcare providers. We offer a range of products and services that aim to improve the safety, efficiency and quality of patient care, with Alcidion solutions contributing more than a billion dollars in annual savings to the global healthcare economy. These solutions are supported by Alcidion’s flagship product Miya Precision, a clinical decision support platform that uses artificial intelligence and machine learning to provide real-time insights and recommendations to clinicians. Miya Precision is designed to enhance existing healthcare IT investment by aligning with clinical workflows and supporting clinicians to make more accurate diagnosis, improve treatment outcomes, and reduce the risk of medical errors.At Alcidion, our focus is to help healthcare providers manage patient information, streamline clinical workflows, and make better informed decisions about patient care.